Drug Insights

Is Recarbrio approved by the FDA?

21 June 2024
3 min read

Yes, Recarbrio is FDA approved. The U.S. Food and Drug Administration (FDA) approved Recarbrio, which is a combination of imipenem, cilastatin, and relebactam, on July 16, 2019.

What is Recarbrio?

Recarbrio is a combination antibiotic consisting of imipenem, cilastatin, and relebactam. This combination belongs to the drug class of carbapenems and beta-lactamase inhibitors. It is formulated as an intravenous powder for injection, with each dose containing 1.25 grams of the active ingredients.

Uses of Recarbrio

Recarbrio is used to treat various complicated infections in adults who have limited or no alternative treatment options. These infections include:

  1. Complicated Urinary Tract Infections (cUTI):
    • Includes pyelonephritis, a type of kidney infection.
    • Caused by bacteria such as Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
  2. Complicated Intra-abdominal Infections (cIAI):
    • Infections within the stomach area.
    • Caused by bacteria such as Bacteroides fragilis, Escherichia coli, and Klebsiella pneumoniae.
  3. Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP):
    • Lung infections acquired in a hospital setting or from the use of ventilators.
    • Caused by bacteria such as Klebsiella pneumoniae, Pseudomonas aeruginosa, and Serratia marcescens.

Dosage

Recarbrio is administered as an intravenous infusion with the typical dosage being 1.25 grams every six hours. The duration of treatment generally ranges from 4 to 14 days depending on the severity and type of infection.

Side Effects

Common Side Effects:

  • Increased blood pressure
  • Nausea, diarrhea, vomiting
  • Abnormal liver function tests
  • Fever
  • Headache
  • Injection site reactions (pain, bruising, swelling, irritation)

Serious Side Effects:

  • Tremors
  • Seizures
  • Severe stomach pain or diarrhea (watery or bloody)

Warnings and Precautions

  • Allergic Reactions: Patients allergic to imipenem, cilastatin, or relebactam should not use Recarbrio.
  • Seizures: Use with caution in patients with a history of seizures.
  • Antibiotic-associated Diarrhea: Diarrhea may indicate a new infection; consult a doctor if severe diarrhea occurs.

Drug Interactions

Recarbrio may interact with other medications such as divalproex sodium, ganciclovir, and valproic acid. Patients should inform their healthcare provider of all medications they are taking to avoid potential interactions.

Conclusion

Recarbrio, approved by the FDA in July 2019, is a vital antibiotic used to treat severe and complicated infections in patients with few or no other treatment options. Its approval underscores its significance in combating resistant bacterial infections, making it a crucial option in the treatment of complicated urinary tract infections, intra-abdominal infections, and certain types of pneumonia.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

FDA Approves Zymeworks' ZW171, a New Bispecific Antibody for Mesothelin-related Tumors
Latest Hotspot
3 min read
FDA Approves Zymeworks' ZW171, a New Bispecific Antibody for Mesothelin-related Tumors
21 June 2024
Zymeworks Receives FDA Approval for ZW171, a New Bispecific Antibody Targeting Mesothelin-related Tumors.
Read →
Is Amlodipine approved by the FDA?
Drug Insights
3 min read
Is Amlodipine approved by the FDA?
21 June 2024
The U.S. Food and Drug Administration (FDA) approved amlodipine, which is marketed under brand names such as Norvasc, Katerzia, and Norliqva, for medical use. This approval was granted on July 8, 2019.
Read →
iTeos and GSK Initiate Phase 3 GALAXIES Lung-301 Trial for Advanced Lung Cancer Treatment
Latest Hotspot
3 min read
iTeos and GSK Initiate Phase 3 GALAXIES Lung-301 Trial for Advanced Lung Cancer Treatment
21 June 2024
iTeos and GSK Launch Phase 3 GALAXIES Lung-301 Trial, Evaluating Belrestotug and Dostarlimab in Untreated, Inoperable Advanced/Metastatic PD-L1 Positive Non-Small Cell Lung Cancer.
Read →
Is Selinexor approved by the FDA?
Drug Insights
3 min read
Is Selinexor approved by the FDA?
21 June 2024
The U.S. Food and Drug Administration (FDA) granted approval for selinexor on an accelerated basis on July 3, 2019.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.